Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview

Arthritis Care and Research

Volumn 61, Issue 10, 2009, Pages 1435-1440

  Obici, Laura ^a   Raimondi, Sara ^b   Lavatelli, Francesca ^a   Bellotti, Vittorio ^b   Merlini, Giampaolo ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; GELATINASE A; INTERSTITIAL COLLAGENASE; MANNOSE BINDING LECTIN 2; MATRIX METALLOPROTEINASE; SERUM AMYLOID A; STROMELYSIN;

ALLELE; AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; AUTOINFLAMMATORY DISEASE; DISEASE PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; KIDNEY INJURY; NEPHROTIC SYNDROME; NONHUMAN; PREVALENCE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEINURIA; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

AMYLOIDOSIS; ANIMALS; COMORBIDITY; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; RHEUMATIC DISEASES; SERUM AMYLOID A PROTEIN;

EID: 70349778661     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24735     Document Type: Review

References (59)

1. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;56:2361-2371 (Pubitemid 46883770)
2. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2006;45:43-49 (Pubitemid 43033873)
3. Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:408-413 (Pubitemid 352003208)
4. Takahashi M, Yokota T, Kawano H, Gondo T, Ishihara T, Uchino F. Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A 1989;415:411-419 (Pubitemid 19241013)
5. Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ. A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 2002;46:1905-1913 (Pubitemid 34774523)
6. Magy N, Benson MD, Liepnieks JJ, Kluve-Beckerman B. Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid 2007;14:51-63. (Pubitemid 46491169)
7. Sponarova J, Nystrom SN, Westermark GT. AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS ONE 2008;3:e3308.
8. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999;274:7172-7181 (Pubitemid 129505006)
9. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 1992;59:1531-1540
10. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004;18:1749-1751 (Pubitemid 39561672)
11. Koivuniemi R, Paimela L, Suomalinen R, Tornroth T, Leirisalo-Repo M. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008;15:262-268
12. El Mansoury TM, Hazenberg BP, el Badawy SA, Ahmed AH, Bijzet J, Limburg PC, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002;61:42-47
13. Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Matsumoto T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996;35:44-49 (Pubitemid 26090363)
14. Gomez-Casanovas E, Sanmarti R, Sole M, Canete JD, Munoz- Gomez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001;44:66-72. (Pubitemid 32113120)
15. Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003;30:948-951 (Pubitemid 36529612)
16. Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 2007;34:371-373 (Pubitemid 46255757)
17. Gratacos J, Orellana C, Sanmarti R, Sole M, Collado A, Gomez- Casanovas E, et al. Secondary amyloidosis in ankylosing spondylitis: a systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997;24:912-915 (Pubitemid 27223627)
18. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003;48:1149-1155 (Pubitemid 36418258)
19. Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al, for the International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-1712
20. Westermark P, Westermark GT. Reflections on amyloidosis in Papua New Guinea. Phil Trans R Soc B 2008;363:3701-3705
21. Saatci U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 1997;15:619-623 (Pubitemid 27351849)
22. Maury CP, Liljestrom M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Tumor necrosis factor α, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheuma- toid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068-3076 (Pubitemid 37409317)
23. Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998;5:262-265
24. Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999;105:360-366 (Pubitemid 29476289)
25. Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:124-127 (Pubitemid 32102202)
26. Utku U, Dilek M, Akpolat I, Bedir A, Akpolat T. SAA1 α/α alleles in Behçet's disease related amyloidosis. Clin Rheumatol 2007;26:927-929 (Pubitemid 46951291)
27. Moriguchi M, Terai C, Kaneko H, Koseki Y, Kajiyama H, Uesato M, et al. A novel single-nucleotide polymorphism at the 5′-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum 2001;44:1266-1272 (Pubitemid 32537524)
28. Yamada T, Okuda Y, Takasugi K, Wang L, Marks D, Benson MD, et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid 2003;10:7-11. (Pubitemid 36520923)
29. Terai C, Kaneko H, Moriguchi M, Koseki Y, Kajiyama H, Tiitinen S, et al. SAA1 gene analysis in Finnish patients with AA amyloidosis. In: Grateau G, Kyle RA, Skinner M, editors. Amyloid and amyloidosis. Boca Raton (FL): CRC Press; 2005. p. 176-178
30. Moriguchi M, Kaneko H, Terai C, Koseki Y, Kajiyama H, Inada S, et al. Relative transcriptional activities of SAA1 promoters polymorphic at position -13(T/C): potential association between increased transcription and amyloidosis. Amyloid 2005;12:26-32. (Pubitemid 40896941)
31. Yamada T, Wada A. Slower clearance of human SAA1.5 in mice: implications for allele specific variation of SAA concentration in human. Amyloid 2003;10:147-150 (Pubitemid 37372398)
32. Lavie G, Zucker-Franklin D, Franklin EC. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med 1978;148:1020-1031 (Pubitemid 9034269)
33. Maury CP, Aittoniemi J, Tiitinen S, Laiho K, Kaarela K, Hurme M. Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Intern Med 2007;262:466-469 (Pubitemid 47404366)
34. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose- binding lectin and its genetic variants. Genes Immun 2006;7:85-94. (Pubitemid 43336050)
35. Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, Yates J, et al. Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 2005;24:4124-4132 (Pubitemid 41752881)
36. Muller D, Roessner A, Rocken C. Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and α2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch 2000;437:521-527
37. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C. Proteolysis of AA amyloid fibril proteins by matrix metalloproteases -1, -2, and 3. Am J Pathol 2001;159:561-570 (Pubitemid 32751086)
38. Van der Hilst JC, Yamada T, Op den Camp HJ, van der Meer JW, Drenth JP, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford) 2008;47:1651-1654
39. SAA) donors by murine macrophages of four different mouse strains. Virchows Arch 1998;432:547-555
40. Sipe JD, Carreras I, Gonnerman WA, Cathcart ES, de Beer MC, de Beer FC. Characterization of the inbred CE/J mouse strain as amyloid resistant. Am J Pathol 1993;143:1480-1485 (Pubitemid 24057118)
41. Yu L, Zhu H, Guo J, de Beer FC, Kindy MS. Expression of mouse apolipoprotein SAA1.1 in CE/J mice: isoform-specific effects on amyloidogenesis. Lab Invest 2000;80:1797-1806 (Pubitemid 32012749)
42. Wang L, Colon W. Effect of zinc, copper and calcium on the structure and stability of serum amyloid A. Biochemistry 2007;46:5562-5569 (Pubitemid 46717278)
43. Ham D, Skoryna SC. Generation of amyloid A protein by the cell lines from amyloid-susceptible and -resistant mice. Scand J Immunol 2004;59:117-122 (Pubitemid 38253543)
44. Fuks A, Zucker-Franklin D. Impaired Kupffer cell function precedes development of secondary amyloidosis. J Exp Med 1985;161:1013-1028 (Pubitemid 15011322)
45. Yamada T, Liepnieks J, Benson MD, Kluve-Beckerman B. Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol 1996;157:901-907 (Pubitemid 26231398)
46. Yamada T, Liepnieks JJ, Kluve-Beckerman B, Benson MD. Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 1995;41:94-97
47. Rocken C, Fandrich M, Stix B, Tannert A, Hortschansky P, Reinheckel T, et al. Cathepsin protease activity modulates amyloid load in extracerebral amyloidosis. J Pathol 2006;210:478-487 (Pubitemid 44830608)
48. Phipps-Yonas H, Pinard G, Ali-Kahn Z. Humoral proinflammatory cytokine and SAA generation profiles and spatiotemporal relationship between SAA and lysosomal cathepsin B and D in murine splenic monocytoid cells during AA amyloidosis. Scand J Immunol 2004;59:168-176 (Pubitemid 38253549)
49. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 2005;102:6473-6477
50. Sugumaran G, Elliott-Bryant R, Phung N, Vitseva O, Kuberan B, Lech M. Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice. Scand J Immunol 2004;60:574-583 (Pubitemid 39665102)
51. Migita K, Yamasaki S, Shibatomi K, Ida H, Kita M, Kawakami A, et al. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Rheumatol 2001;123:408-411 (Pubitemid 32289959)
52. Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001;166:2801-2807 (Pubitemid 32173521)
53. Lee HY, Kim SD, Shim JW, Lee SY, Lee H, Cho KH, et al. Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol 2008;181:4332-4339
54. Chen B, Yang SK, Lan CY, Chuang YJ. A systems biology approach to construct the gene regulatory network of systemic inflammation via microarrays and databases mining. BMC Med Genomics 2008;1:46.
55. Ray D, Wu A, Wilkinson JE, Murphy HS, Lu Q, Kluve-Beckerman B, et al. Aging in heterozygous Dnm1-deficient mice: effects on survival, the DNA methylation genes, and the development of amyloidosis. J Gerontol A Biol Sci Med Sci 2006;61A:115-124 (Pubitemid 43334607)
56. Waldestrom H. On the formation and disappearance of amyloid in man. Acta Chir Scand 1928;63:479-530.
57. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649-655 (Pubitemid 35440848)
58. Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008;18:109-118
59. Tennent GA, Lovat MB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995;92:4299-4303